GTx Restarts Development Of Prostate Cancer Drug Capesaris
This article was originally published in The Pink Sheet Daily
Executive Summary
GTx managed to convince FDA to lift its clinical hold, arguing the mid-stage prostate cancer drug would be safe to test again in patients at lower dosages than before.